New CEO for CLI Innovator LimFlow SA

LimFlow SA has announced the appointment of ex-Direct Flow Medical VP, Daniel Rose as Chief Executive Officer (CEO), while former CEO and co-founder Timothy Lenihan has transitioned to Chief Technology Officer and maintains a role on the company’s Board of Directors.

Background

Developer of Endovascular technology, LimFlow SA reckons to be transforming the treatment of critical limb ischemia (CLI). New to our pages, the company, originally supported by the Europe-based MD Start I accelerator project, has developed a purely percutaneous approach to re-establishing lower limb perfusion in patients where traditional revascularization options are not feasible. In so doing, they aim to help heal chronic wounds and enable patients to avoid major amputation. The system employs two ultrasound-guided catheters, one venous and one arterial, to install several covered nitinol stents, creating an arterio-venous fistula and channeling blood supply to the ischemic foot.

First-in-Man and CE Mark clinical studies have been completed for the LimFlow System. The company has also submitted an application to obtain the CE Mark.

Until recently Daniel Rose served as vice president and general manager, Europe for Direct Flow Medical, an innovative developer of transcatheter heart valve technology.

Company comments

“Dan has strong experience in leading medical device businesses and commercializing groundbreaking cardiovascular technologies in Europe and beyond,” said Mr. Lenihan. “His experience will be invaluable as we realize our mission to make LimFlow a leading innovator that enables physicians to change the lives of patients living with CLI.”

Incumbent comments

“LimFlow is transforming the treatment of patients facing the loss of a limb due to critical limb ischemia and chronic wounds, a growing clinical need in the face of the diabetes and vascular disease epidemics,” said Mr. Rose. “I am impressed with their innovative approach to solving this problem and the promising clinical results to date, and I look forward to leading the team to make this the standard of care for treating ‘no option’ CLI.”

Source: LimFlow SA

 

Share your thoughts

Your email address will not be published. Required fields are marked *